Actively Recruiting
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-02-25
100
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The project aims to perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using targeted MSLN-specific imaging agents (taking \[68Ga\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
CONDITIONS
Official Title
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to sign informed consent
- Willingness to comply with study procedures
- Adult (18 years or older), any gender
- Patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, or lung adenocarcinoma with supporting evidence
- Good general health condition
- Meet specific laboratory test results
- Females of childbearing potential using contraception for at least one month before screening and during the study
- Other specified entry criteria
You will not qualify if you...
- Unable to complete PET/MR or PET/CT examination (e.g., inability to lie down, claustrophobia, radiophobia)
- Presence of other health conditions
- Known allergy to MSLN antibody fragments or excipients; fasting blood glucose over 11.0 mmol/L before 18F-FDG injection
- History of using other drugs affecting the study
- Poor compliance as judged by investigator
- Pregnancy or lactation
- Other factors deemed unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wuhan Union Hospital, China
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
X
Xiaoli Lan, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here